NY-EDELMAN
Edelman today announced the global launch of Edelman Smithfield, a financial communications boutique that specializes in the financial markets and strategic situations, serving clients in the United States, EMEA, Asia and beyond. The global launch brings together under one brand Edelman’s Financial Communications and Financial Services teams, combining specialized industry knowledge with global scale and localized expertise, while remaining connected to and integrated with Edelman’s full capabilities. Lex Suvanto will serve as Edelman Smithfield Global CEO.
Edelman Smithfield is focused on advising senior leaders and management teams navigating complex matters that impact reputation and valuation. The firm has deep expertise serving and communicating to the financial markets and is comprised of two primary practice areas:
- Partnering with companies in the financial markets to help them protect, promote and evolve their reputation. Edelman Smithfield is a leading communications advisor in the financial markets, working with investment firms, private equity and venture capital funds, hedge funds, banks, insurers, fintech, crypto and other financial markets participants to develop and execute tailored communications programs that build trust and strengthen reputations in the marketplace.
- Partnering with companies navigating and communicating with the financial markets and during strategic situations. Edelman Smithfield advises boards of directors, management teams and communications professionals on high impact strategic situations, such as mergers, acquisitions, IPOs, bankruptcies and restructurings, shareholder activism, litigation, management changes and regulatory matters, as well as ongoing engagement with the investment community, including investor relations and critical ESG matters.
Richard Edelman, CEO of Edelman, said, “The financial communications team has built an incredible platform and has advised on some of the highest profile clients and situations over the past several years. We continue to see significant demand from both existing and new clients for the work that they are leading, especially given the volatility and complexity of the global financial markets. There’s tremendous opportunity ahead, and we will continue to invest in Edelman Smithfield to ensure the team is well placed to define the next generation of financial communications.”
Edelman Smithfield is already a leading player in the financial communications industry. The firm’s asset management clients professionally manage more than $20 trillion combined, which, when coupled with insights from the annual Investor Trust survey, translates into a unique understanding of the global institutional investor landscape; Edelman Smithfield has advised on hundreds of transactions in the last five years, including some of the most prominent mergers and acquisitions, IPOs and restructurings.
Lex Suvanto, Global CEO of Edelman Smithfield, said, “We have a singular goal of building a financial communications powerhouse globally, and Edelman is providing the investment and runway to make this a reality. We are the only firm that specializes in the financial markets and strategic situations while bringing the reach and resources of broader Edelman. Together as a global team and with a unified banner and strategy, we will unlock new opportunities, while always prioritizing excellent client work, conducting ourselves with integrity and attracting and empowering an incredible team of dedicated advisors.”
Edelman Smithfield brings a strong leadership team with an impeccable track record of helping clients navigate the complex and dynamic financial markets. Global and regional leadership appointments include:
- Lex Suvanto, Global CEO
- John Kiely, Chairman of EMEA
- Andrew Wilde, Global Head of Financial Services
- Josh Hochberg, Global Chief Operating Officer
- Katie Spring, President, United States
- Alex Simmons, Head of EMEA
- Jason Leow, Head of APAC
Edelman Smithfield also includes leaders and teams in a total of 25 cities and 15 countries around the world.
In 2015, Edelman acquired Smithfield, a UK-based financial communications firm, as part of its ongoing investment and growth in financial communications. Since that time, the Edelman Smithfield brand has been rolled out in Germany, the Middle East and Canada. Edelman plans to commit significant resources to the continued expansion of the Edelman Smithfield platform in key markets around the world.
About Edelman
Edelman is a global communications firm that partners with businesses and organizations to evolve, promote and protect their brands and reputations. Our 6,000 people in more than 60 offices deliver communications strategies that give our clients the confidence to lead and act with certainty, earning the trust of their stakeholders. Our honors include the Cannes Lions Grand Prix for PR; Advertising Age’s 2019 A-List; the Holmes Report’s 2018 Global Digital Agency of the Year; and, five times, Glassdoor’s Best Places to Work. Since our founding in 1952, we have remained an independent, family-run business. Edelman owns specialty companies Edelman Data x Intelligence (research, data) and United Entertainment Group (entertainment, sports, lifestyle).
About Edelman Smithfield
Edelman Smithfield is a financial communications boutique that specializes in the financial markets and strategic situations with the full reach and resources of Edelman. The Edelman Smithfield team comprises approximately 250 advisors across more than 25 cities and 15 countries serving an expansive roster of top organizations around the world. www.EdelmanSmithfield.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom